Screener
Tectonic Therapeutics TECX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Tectonic Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Tectonic Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:19 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212016
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $236,894 | $253,798 |
| Prepaid expenses and other current assets | 2,997 | 2,974 |
| Restricted cash | — | 587 |
| Total current assets | 239,891 | 257,359 |
| Property and equipment, net | 1,020 | 1,185 |
| Finance right-of-use assets, net | 410 | 495 |
Item 1. Financial Statements.
FAQ
- What is Tectonic Therapeutics's cash & equivalents?
- Tectonic Therapeutics (TECX) reported cash & equivalents of $236.89M in Q1 2026.
- How has Tectonic Therapeutics's cash & equivalents changed year-over-year?
- Tectonic Therapeutics's cash & equivalents decreased by 22.8% year-over-year, from $306.83M to $236.89M.
- What is the long-term trend for Tectonic Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Tectonic Therapeutics's cash & equivalents has grown at a -0.5% compound annual growth rate (CAGR), from $259.68M to $253.8M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Tectonic Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude